ARTICLE | Clinical News

Allos to continue Efaproxyn Phase III

April 5, 2006 12:25 AM UTC

ALTH said that an IDMC recommended continuation of the Phase III ENRICH trial of Efaproxyn efaproxiral to treat brain metastases originating from breast cancer, following an interim analysis triggered by 94 patient deaths. The open-label, international trial, which will enroll 360 patients, is comparing the effect of whole brain radiation therapy with supplemental oxygen with or without Efaproxyn and is measuring survival as the primary endpoint. A second interim analysis at 188 patient deaths is expected next half and, if necessary, a final analysis at 282 deaths is expected in the first half of 2007. ...